Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals

What this episode covers

Visit https://www.peervoice.com/NXK860 to view the entire programme with slides. After completing “Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals”, participants will be able to: Explain the current evidence-basis and recommendations for the use, timing, and sequencing of radiopharmaceuticals within comprehensive treatment plans for patients with metastatic castration-resistant prostate cancer (mCRPC); Evaluate the rationale for, and emerging evidence from, ongoing studies related to the optimisation of radiopharmaceutical use across the treatment continuum for patients with mCRPC; and Design holistic, appropriately sequenced treatment plans for patients with mCRPC which appropriately integrate radiopharmaceuticals based on current evidence and patient-specific preferences and goals.

Distinct summary based on available episode metadata or transcript content.